Type 1 diabetes screening: need for ethical, equity, and health systems perspective

In October 2024, the ICD-10 codes were updated to include presymptomatic stages of type 1 diabetes, prompting recommendations for population screening. The use of teplizumab to delay progression to clinical diabetes offers new possibilities, but raises concerns about medicalizing early stages, psychological impacts, access to treatment, and healthcare equity. This article explores the challenges of integrating population screening and disease-modifying therapies into clinical practice, considering ethical, financial, and health system factors.